Drug intelligence / Profile preview

HRS-1167 + famitinib + camrelizumab

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

HRS-1167 + famitinib + camrelizumab is an investigational, chemotherapy-free neoadjuvant combination regimen being evaluated for the treatment of germline BRCA-mutated (gBRCAm), HER2-negative breast cancer. The regimen consists of three distinct agents: HRS-1167, a highly selective, next-generation poly (ADP-ribose) polymerase 1 (PARP1) inhibitor; famitinib, a multi-targeted tyrosine kinase inhibitor (TKI) that inhibits VEGFR2, PDGFR, and c-kit; and camrelizumab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. Developed by Jiangsu Hengrui Pharmaceuticals and currently being studied in a Phase II trial led by Fudan University, this combination aims to leverage synthetic lethality (via PARP1 inhibition), anti-angiogenesis (via TKI activity), and immune checkpoint blockade to provide an effective treatment option without the toxicity associated with traditional chemotherapy.

Brand names: AiRuiKa
Other names: HRS-1167 + famitinibHRS-1167 + famitinib + camrelizumab

Targets

PDCD1 (Programmed cell death protein 1 receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)ULBP2 (UL16-binding protein 2)

Beyond the preview

Go deeper on HRS-1167 + famitinib + camrelizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-1167 + famitinib + camrelizumab.

Explore the full profile